| Downgrades | Buy Hold | X | ||
|
$10 $1 |
||||
| Downgrades | Buy Neutral | X | ||
| Downgrades | Buy Hold | X | ||
| Downgrades | Buy Hold | X | ||
|
$6 $1 |
||||
| Downgrades | Neutral Underperform | X | ||
|
$13 $6 |
||||
| Upgrades | Neutral Overweight | X | ||
|
$17 $20 |
||||
| Resumed | Buy | X | ||
| Reiterated | Buy | X | ||
|
$31 $30 |
||||
| Resumed | Buy | X | ||
| Initiated | Neutral | X | ||
| Initiated | Overweight | X | ||
| Initiated | Buy | X | ||
| Reiterated | Buy | X | ||
|
$22 $26 |
||||
| Reiterated | Buy | X | ||
|
$24 $26 |
||||
| Resumed | Buy | X | ||
| Upgrades | Neutral Buy | X | ||
CARA Cara Therapeutics, Inc.
Quotes: Barrons • SeekingAlpha • NASDAQ • Bloomberg • WSJ
Cara Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing chemical entities designed to alleviate pain and pruritus by focusing on kappa opioid receptors. It is developing a class of product candidates that target the body's peripheral nervous system. The Company operates through the activities related to the discovery and development of therapeutics to treat serious medical conditions, including pain and pruritus. Its product candidate pipeline includes IV CR845 for acute pain; IV CR845 for uremic pruritus; Oral CR845 for acute and chronic pain, and CR701 for neuropathic and inflammatory pain. IV CR845 is an injectable version of peripheral kappa opioid receptor agonist, which is intended for the treatment of acute pain in an acute care setting. CR845 has exhibited anti-pruritic, or anti-itch, potency in standard preclinical models.
